Alok S Bansal, MD
Ophthalmology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 7 carriers
- Offices
- 3
- Since medical school
- 20 years
- Northeastern Ohio University College of Medicine, 2006
Offices
3 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
30 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bansal’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A120272 · Current
Licensed to practise in California · since 2012 · expires 2027-09-30 · Northeastern Ohio Universities College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Ophthalmology - Ophthalmology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,573,407
Medicare paid this office $2,573,407 for 722 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 225 | $1,829,692 | None |
| Injection, ranibizumab, 0.1 mg | 41 | $178,514 | None |
| Injection of drug into eye | 278 | $175,119 | $117 |
| Imaging of retina | 702 | $100,641 | $41 |
| Established patient problem focused exam of visual system | 472 | $85,391 | $89 |
See all 14 services
| Injection, aflibercept, 1 mg | 225 | $1,829,692 | None |
| Injection, ranibizumab, 0.1 mg | 41 | $178,514 | None |
| Injection of drug into eye | 278 | $175,119 | $117 |
| Imaging of retina | 702 | $100,641 | $41 |
| Established patient problem focused exam of visual system | 472 | $85,391 | $89 |
| Return visit (30+ min) | 257 | $65,116 | $132 |
| Injection, faricimab-svoa, 0.1 mg | 12 | $49,845 | None |
| New patient visit (45+ min) | 145 | $22,399 | $154 |
| Established patient complete exam of visual system | 133 | $16,240 | $119 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 43 | $7,633 | $178 |
| Short return visit (20+ min) | 90 | $4,485 | $46 |
| New patient complete exam of visual system | 25 | $3,735 | $149 |
| Photography of the retina | 49 | $2,506 | $35 |
| 2d ultrasound scan of eye tissue and structures | 17 | $1,669 | $49 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of drug into eye | 1,393 | 1,698 | 1,956 | 1,932 | 1,749 | 1,502 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
722 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 31% · Women 56% · Also on Medicaid 15% · Health risk score 1.40. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 34% · Coronary heart disease 27% · Chronic kidney disease 25% · Atrial fibrillation 22% · Heart failure 17% · Cancer 16% · Depression 12% · COPD 11% · Dementia 7% · Stroke 7%.
The office billed $7,857,162, Medicare allowed $3,274,281 and paid $2,573,407; for 12,614 services of 31 kinds; $2,066,600 of it was for drugs given in the office and $506,807 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 722 | 12,614 | 79 | 1.40 | $7,857,162 | $2,573,407 |
| 2023 | 641 | 14,019 | 79 | 1.40 | $8,856,246 | $3,017,822 |
| 2022 | 683 | 13,107 | 79 | 1.38 | $9,564,730 | $3,382,341 |
| 2021 | 734 | 14,118 | 79 | 1.35 | $9,324,033 | $3,494,672 |
| 2020 | 602 | 12,860 | 79 | 1.37 | $7,750,020 | $2,937,295 |
| 2019 | 685 | 10,632 | 79 | 1.46 | $6,359,603 | $2,473,049 |
| 2018 | 727 | 10,707 | 78 | 1.42 | $6,720,067 | $2,674,096 |
| 2017 | 682 | 9,707 | 78 | 1.42 | $5,413,972 | $2,237,792 |
| 2016 | 624 | 8,733 | 78 | 1.40 | $3,334,369 | $1,706,352 |
| 2015 | 579 | 6,736 | 78 | 1.32 | $2,128,078 | $1,070,558 |
| 2014 | 576 | 5,248 | 78 | 1.39 | $1,317,915 | $710,531 |
| 2013 | 477 | 4,650 | 77 | 1.30 | $1,228,922 | $713,753 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Injection, aflibercept, 1 mg | 208 | $2,103,329 | None |
| Injection, ranibizumab, 0.1 mg | 58 | $379,286 | None |
| Injection of drug into eye | 280 | $195,930 | $112 |
| Imaging of retina | 625 | $92,685 | $40 |
| Injection, faricimab-svoa, 0.1 mg | 22 | $78,156 | None |
| Established patient problem focused exam of visual system | 345 | $75,902 | $84 |
| Established patient complete exam of visual system | 185 | $23,170 | $109 |
| Short return visit (20+ min) | 175 | $21,342 | $84 |
| New patient visit (45+ min) | 127 | $17,861 | $141 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 28 | $3,540 | $126 |
| Photography of the retina | 52 | $2,621 | $35 |
| 2d ultrasound scan of eye tissue and structures | 16 | $1,455 | $47 |
2022: 11 services
| Injection, aflibercept, 1 mg | 224 | $2,159,042 | None |
| Injection, ranibizumab, 0.1 mg | 73 | $702,525 | None |
| Injection of drug into eye | 309 | $211,999 | $110 |
| Established patient problem focused exam of visual system | 438 | $117,617 | $85 |
| Imaging of retina | 657 | $93,121 | $39 |
| Established patient complete exam of visual system | 230 | $34,770 | $114 |
| New patient visit (45+ min) | 149 | $21,982 | $148 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 80 | $9,902 | $122 |
| Photography of the retina | 96 | $5,307 | $37 |
| Compounded drug, not otherwise classified | 16 | $4,640 | None |
| 2d ultrasound scan of eye tissue and structures | 20 | $2,040 | $42 |
2021: 12 services
| Injection, aflibercept, 1 mg | 211 | $1,840,804 | None |
| Injection, ranibizumab, 0.1 mg | 102 | $1,049,495 | None |
| Injection of drug into eye | 322 | $223,824 | $114 |
| Established patient problem focused exam of visual system | 428 | $131,697 | $88 |
| Imaging of retina | 599 | $87,824 | $41 |
| Established patient complete exam of visual system | 342 | $51,306 | $111 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 214 | $25,713 | $117 |
| Photography of the retina | 346 | $19,437 | $36 |
| New patient visit (45+ min) | 135 | $18,602 | $138 |
| Compounded drug, not otherwise classified | 28 | $10,678 | None |
| New patient visit (60+ min) | 14 | $2,737 | $195 |
| 2d ultrasound scan of eye tissue and structures | 27 | $2,303 | $48 |
2020: 12 services
| Injection, aflibercept, 1 mg | 137 | $1,335,268 | None |
| Injection, ranibizumab, 0.1 mg | 97 | $1,025,998 | None |
| Injection of drug into eye | 256 | $166,465 | $98 |
| Established patient problem focused exam of visual system | 334 | $146,926 | $87 |
| Imaging of retina | 411 | $66,401 | $40 |
| Established patient complete exam of visual system | 371 | $56,157 | $102 |
| Photography of the retina | 454 | $33,011 | $43 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 275 | $30,240 | $101 |
| New patient visit (45+ min) | 127 | $17,161 | $135 |
| Compounded drug, not otherwise classified | 23 | $12,855 | None |
| New patient visit (60+ min) | 18 | $3,405 | $189 |
| 2d ultrasound scan of eye tissue and structures | 21 | $2,508 | $51 |
2019: 14 services
| Injection, aflibercept, 1 mg | 141 | $1,196,716 | None |
| Injection, ranibizumab, 0.1 mg | 102 | $818,518 | None |
| Established patient problem focused exam of visual system | 440 | $135,148 | $83 |
| Injection of drug into eye | 267 | $128,175 | $92 |
| Imaging of retina | 520 | $67,533 | $40 |
| Established patient complete exam of visual system | 285 | $39,348 | $101 |
| Photography of the retina | 290 | $19,657 | $48 |
| New patient visit (45+ min) | 103 | $14,284 | $139 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 118 | $11,645 | $93 |
| Compounded drug, not otherwise classified | 21 | $4,508 | None |
| New patient visit (60+ min) | 20 | $3,493 | $175 |
| 2d ultrasound scan of eye tissue and structures | 19 | $1,857 | $60 |
| Examination of eye by ophthalmoscope with retinal drawing | 15 | $538 | $27 |
| Imaging of optic nerve | 13 | $367 | $26 |
2018: 17 services
| Injection, aflibercept, 1 mg | 165 | $1,592,405 | None |
| Injection, ranibizumab, 0.1 mg | 82 | $563,885 | None |
| Injection of drug into eye | 264 | $139,363 | $92 |
| Established patient problem focused exam of visual system | 334 | $118,829 | $82 |
| Imaging of retina | 543 | $75,440 | $40 |
| Established patient complete exam of visual system | 431 | $72,549 | $105 |
| New patient visit (45+ min) | 160 | $22,693 | $142 |
| Photography of the retina | 296 | $19,169 | $53 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 13 | $14,720 | $1,132 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 165 | $14,378 | $85 |
| Compounded drug, not otherwise classified | 27 | $7,168 | None |
| 2d ultrasound scan of eye tissue and structures | 27 | $3,976 | $72 |
| New patient visit (60+ min) | 14 | $2,522 | $180 |
| Long return visit (40+ min) | 11 | $1,232 | $112 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $887 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $591 | $23 |
| Imaging of optic nerve | 16 | $435 | $27 |
2017: 16 services
| Injection, aflibercept, 1 mg | 173 | $1,514,847 | None |
| Injection, ranibizumab, 0.1 mg | 23 | $219,663 | None |
| Injection of drug into eye | 232 | $128,153 | $91 |
| Established patient problem focused exam of visual system | 292 | $102,533 | $79 |
| Established patient complete exam of visual system | 438 | $76,980 | $105 |
| Imaging of retina | 514 | $66,327 | $39 |
| Photography of the retina | 331 | $23,823 | $67 |
| New patient visit (45+ min) | 170 | $23,664 | $139 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 287 | $22,125 | $76 |
| Compounded drug, not otherwise classified | 70 | $15,140 | None |
| Destruction of leaking blood vessels of retina using laser | 14 | $5,519 | $325 |
| Examination of eye by ophthalmoscope with retinal drawing | 104 | $4,851 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 70 | $3,702 | $23 |
| New patient visit (60+ min) | 17 | $3,211 | $189 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,613 | $77 |
| Imaging of optic nerve | 18 | $617 | $34 |
2016: 15 services
| Injection, aflibercept, 1 mg | 87 | $923,981 | None |
| Injection, ranibizumab, 0.1 mg | 29 | $263,882 | None |
| Injection of drug into eye | 202 | $116,839 | $91 |
| Established patient problem focused exam of visual system | 289 | $98,919 | $80 |
| Imaging of retina | 473 | $70,294 | $42 |
| Established patient complete exam of visual system | 348 | $61,186 | $107 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 160 | $31,661 | $101 |
| New patient visit (45+ min) | 220 | $29,153 | $133 |
| Compounded drug, not otherwise classified | 109 | $27,092 | None |
| Photography of the retina | 221 | $16,183 | $70 |
| Removal of eye fluid (vitreous) between lens and retina | 17 | $10,773 | $598 |
| 2d ultrasound scan of eye tissue and structures | 30 | $5,015 | $84 |
| New patient visit (60+ min) | 26 | $4,240 | $163 |
| Examination of eye by ophthalmoscope with retinal drawing | 98 | $4,054 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 69 | $2,878 | $23 |
2015: 16 services
| Injection, aflibercept, 1 mg | 48 | $404,794 | None |
| Injection, ranibizumab, 0.1 mg | 32 | $203,250 | None |
| Injection of drug into eye | 185 | $89,928 | $96 |
| Established patient problem focused exam of visual system | 322 | $64,491 | $78 |
| Imaging of retina | 420 | $63,266 | $43 |
| Established patient complete exam of visual system | 349 | $58,031 | $109 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 156 | $31,550 | $104 |
| New patient visit (45+ min) | 194 | $27,355 | $141 |
| Unclassified biologics | 104 | $19,537 | None |
| Photography of the retina | 230 | $18,559 | $72 |
| Compounded Drug, Not Otherwise Classified | 76 | $8,254 | $54 |
| 2d ultrasound scan of eye tissue and structures | 38 | $7,647 | $90 |
| Examination of eye by ophthalmoscope with retinal drawing | 100 | $4,390 | $26 |
| New patient visit (60+ min) | 18 | $2,964 | $165 |
| Return visit (30+ min) | 20 | $1,844 | $92 |
| Examination of eye by ophthalmoscope with retinal drawing | 24 | $861 | $24 |
2014: 13 services
| Injection, ranibizumab, 0.1 mg | 29 | $181,026 | None |
| Injection, aflibercept, 1 mg | 30 | $173,677 | None |
| Injection of drug into eye | 135 | $55,694 | $93 |
| Established patient problem focused exam of visual system | 286 | $52,742 | $79 |
| Imaging of retina | 370 | $49,148 | $43 |
| New patient visit (45+ min) | 277 | $39,349 | $142 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 183 | $37,950 | $103 |
| Established patient complete exam of visual system | 215 | $25,262 | $103 |
| Photography of the retina | 299 | $25,046 | $73 |
| Unclassified biologics | 87 | $17,571 | None |
| 2d ultrasound scan of eye tissue and structures | 30 | $3,713 | $86 |
| Examination of eye by ophthalmoscope with retinal drawing | 102 | $2,994 | $26 |
| Examination of eye by ophthalmoscope with retinal drawing | 34 | $809 | $22 |
2013: 13 services
| Injection, ranibizumab, 0.1 mg | 26 | $245,938 | None |
| Injection, aflibercept, 1 mg | 30 | $154,856 | None |
| Established patient problem focused exam of visual system | 307 | $64,196 | $77 |
| Injection of drug into eye | 123 | $54,302 | $91 |
| Imaging of retina | 252 | $34,433 | $43 |
| New patient visit (45+ min) | 215 | $30,452 | $142 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 126 | $26,078 | $106 |
| Photography of the retina | 256 | $22,735 | $70 |
| Unclassified biologics | 85 | $15,537 | None |
| Established patient complete exam of visual system | 106 | $13,664 | $116 |
| 2d ultrasound scan of eye tissue and structures | 30 | $5,008 | $89 |
| New patient visit (30+ min) | 11 | $1,117 | $102 |
| Examination of eye by ophthalmoscope with retinal drawing | 12 | $334 | $26 |
Medicaid work
$456,719 in 2024
Medicaid paid $456,719 for 2,027 billed services this clinician did in 2024, up to 54 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 267 | $266,757 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 489 | $146,758 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 746 | $21,057 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 452 | $17,663 |
| Short return visit (20+ min) | 36 | $2,284 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $1,576 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 12 | $624 |
| Return visit (30+ min) | 13 | $0 |
| 2024 | 2,027 | 8 | 54 | $456,719 |
| 2023 | 2,821 | 6 | 54 | $812,619 |
| 2022 | 2,759 | 6 | 52 | $902,761 |
| 2021 | 2,807 | 6 | 46 | $1,010,876 |
| 2020 | 2,367 | 6 | 41 | $923,263 |
| 2019 | 1,548 | 5 | 53 | $301,773 |
| 2018 | 1,566 | 6 | 37 | $809,073 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 473 | $543,029 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 709 | $210,553 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 863 | $24,998 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 562 | $24,377 |
| Injection, bevacizumab, 10 mg | 199 | $9,145 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $517 |
2022
| Aflibercept injection | 590 | $683,030 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 699 | $175,892 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 596 | $21,922 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 792 | $20,654 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 49 | $806 |
| Injection, bevacizumab, 10 mg | 33 | $457 |
2021
| Aflibercept injection | 589 | $773,530 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 752 | $192,201 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 637 | $21,682 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 579 | $12,141 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 238 | $10,306 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $1,016 |
2020
| Aflibercept injection | 361 | $700,993 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 617 | $174,247 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 683 | $22,675 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 274 | $12,967 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 409 | $10,852 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 23 | $1,529 |
2019
| Aflibercept injection | 63 | $150,098 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 350 | $112,432 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 569 | $18,685 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 406 | $12,496 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 160 | $8,061 |
2018
| Aflibercept injection | 187 | $626,845 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 415 | $144,215 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 441 | $17,213 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 407 | $15,113 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 102 | $5,236 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 14 | $451 |
Drugs they prescribed that Part D paid
$8,846
Pharmacies billed $8,846 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 128) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
86 generic and 42 brand-name prescriptions · $8,846 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Difluprednate | 18 | $2,598 | $144 |
| Prednisolone Acetate | 30 | $1,565 | $52 |
| Neomycin-Polymyxin-Dexameth | 45 | $525 | $12 |
| Ketorolac Tromethamine | 12 | $322 | $27 |
Year by year
| 2024 | 128 | 44 | 0% (0) | 33% | $8,846 |
| 2023 | 76 | 36 | 0% (0) | 30% | $3,307 |
| 2022 | 110 | 29 | 0% (0) | 46% | $8,288 |
| 2021 | 125 | 49 | 0% (0) | 41% | $8,149 |
| 2020 | 193 | 51 | None | 45% | $13,580 |
| 2019 | 180 | 59 | 0% (0) | 47% | $14,932 |
| 2018 | 196 | 53 | None | 46% | $13,614 |
| 2017 | 143 | 61 | None | 44% | $9,129 |
| 2016 | 203 | 75 | None | 44% | $11,713 |
| 2015 | 254 | 76 | None | 52% | $18,834 |
| 2014 | 215 | 77 | None | None | $13,959 |
| 2013 | 232 | 72 | 9% (20) | None | $32,410 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Prednisolone Acetate | 13 | $584 | $45 |
| Neomycin-Polymyxin-Dexameth | 24 | $360 | $15 |
2022: 4 drugs
| Alphagan P | 20 | $4,334 | $217 |
| Prednisolone Acetate | 21 | $729 | $35 |
| Neomycin-Polymyxin-Dexameth | 30 | $460 | $15 |
| Dorzolamide-Timolol | 11 | $207 | $19 |
2021: 5 drugs
| Alphagan P | 20 | $4,227 | $211 |
| Prednisolone Acetate | 20 | $829 | $41 |
| Neomycin-Polymyxin-Dexameth | 26 | $332 | $13 |
| Dorzolamide-Timolol | 16 | $262 | $16 |
| Latanoprost | 11 | $123 | $11 |
2020: 5 drugs
| Alphagan P | 23 | $4,819 | $210 |
| Prednisolone Acetate | 29 | $1,684 | $58 |
| Dorzolamide-Timolol | 14 | $554 | $40 |
| Neomycin-Polymyxin-Dexameth | 36 | $538 | $15 |
| Latanoprost | 28 | $475 | $17 |
2019: 5 drugs
| Alphagan P | 12 | $2,400 | $200 |
| Prednisolone Acetate | 31 | $1,537 | $50 |
| Neomycin-Polymyxin-Dexameth | 34 | $564 | $17 |
| Latanoprost | 28 | $372 | $13 |
| Timolol Maleate | 15 | $114 | $8 |
2018: 6 drugs
| Alphagan P | 13 | $2,346 | $180 |
| Prednisolone Acetate | 47 | $2,178 | $46 |
| Neomycin-Polymyxin-Dexameth | 33 | $439 | $13 |
| Latanoprost | 28 | $378 | $14 |
| Dorzolamide-Timolol | 12 | $181 | $15 |
| Timolol Maleate | 24 | $167 | $7 |
2017: 4 drugs
| Prednisolone Acetate | 42 | $1,455 | $35 |
| Neomycin-Polymyxin-Dexameth | 30 | $416 | $14 |
| Latanoprost | 11 | $122 | $11 |
| Timolol Maleate | 12 | $77 | $6 |
2016: 4 drugs
| Bromfenac | 13 | $3,043 | $234 |
| Prednisolone Acetate | 58 | $2,855 | $49 |
| Neomycin-Polymyxin-Dexameth | 50 | $829 | $17 |
| Ketorolac Tromethamine | 13 | $447 | $34 |
2015: 6 drugs
| Nevanac | 28 | $6,542 | $234 |
| Prednisolone Acetate | 73 | $3,635 | $50 |
| Neomycin-Polymyxin-Dexameth | 40 | $643 | $16 |
| Ketorolac Tromethamine | 13 | $398 | $31 |
| Dorzolamide-Timolol | 12 | $369 | $31 |
| Timolol Maleate | 13 | $117 | $9 |
2014: 6 drugs
| Bromfenac | 15 | $2,878 | $192 |
| Prednisolone Acetate | 45 | $2,363 | $53 |
| Alphagan P | 16 | $1,540 | $96 |
| Neomycin-Polymyxin-Dexameth | 39 | $677 | $17 |
| Ketorolac Tromethamine | 11 | $271 | $25 |
| Latanoprost | 15 | $195 | $13 |
2013: 6 drugs
| Bromfenac | 18 | $2,548 | $142 |
| Prednisolone Acetate | 66 | $1,244 | $19 |
| Alphagan P | 11 | $954 | $87 |
| Neomycin-Polymyxin-Dexameth | 24 | $436 | $18 |
| Latanoprost | 13 | $170 | $13 |
| Hydrocodone-Acetaminophen | 16 | $61 | $4 |
Money from drug and device companies
$30 in 2025
| 2025 | 1 | 1 | None | $30 |
| 2023 | 3 | 3 | None | $322 |
| 2022 | 3 | 3 | None | $72 |
| 2021 | 1 | 1 | None | $27 |
| 2019 | 1 | 1 | None | $417 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $30 | 1 payment
|
See the published payment
| Regeneron Healthcare Solutions | Meals · 2025-05-14 | Eylea Hd | $30 |
See earlier years (2023, 2022, 2021, 2019)
2023: $322
| Alcon Vision | Constellation | $150 | 1 payment
|
| Genentech USA | None | $149 | 1 payment
|
| Alimera Sciences | Yutiq | $23 | 1 payment
|
2022: $72
| Alimera Sciences | Iluvien | $25 | 1 payment
|
| Genentech USA | Vabysmo | $24 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $23 | 1 payment
|
2021: $27
| Regeneron Healthcare Solutions | Eylea | $27 | 1 payment
|
2019: $417
| Allergan | None | $417 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1568646776
- Licence
- CA A120272California A120272: Current · expires 2027-09-30
- Trained
- Northeastern Ohio University College of Medicine, 2006 · 20 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 2485 Hospital Dr, Ste 200, Mountain View, CA, 94040
- NPI first listed
- 2007-12-24
- NPI last updated
- 2017-12-15
This is when the NPI record was last certified, not a medical board exam.